Area of research
Oncology · Immunology
Research interest
Research interests include Immunotherapy and Immune Responses, Cancer Immunotherapy and Biomarkers, Bladder and Urothelial Cancer Treatments, and Monoclonal and Polyclonal Antibodies Research.
A bispecific CD40 agonistic antibody allowing for antibody-peptide conjugate formation to enable cancer-specific peptide delivery, resulting in improved T Cell proliferation and anti-tumor immunity in mice
A bispecific CD40 agonistic antibody allowing for antibody-peptide conjugate formation to enable cancer-specific peptide delivery, resulting in improved T proliferation and anti-tumor immunity in mice.
Bridging responses to a human telomerase reverse transcriptase-based peptide cancer vaccine candidate in a mechanism-based model.
MALT1 inhibition suppresses antigen-specific T cell responses.
Correction: Single-cell RNAseq and longitudinal proteomic analysis of a novel semi-spontaneous urothelial cancer model reveals tumor cell heterogeneity and pretumoral urine protein alterations.
Correlates of protection and viral load trajectories in omicron breakthrough infections in triple vaccinated healthcare workers
Correlates of protection and viral load trajectories in omicron breakthrough infections in triple vaccinated healthcare workers.
Elevated levels of MMP12 sourced from macrophages are associated with poor prognosis in urothelial bladder cancer.
Antibodies from serum and CSF of multiple sclerosis patients bind to oligodendroglial and neuronal cell-lines.
Epitopes Displayed in a Cyclic Peptide Scaffold Bind SARS-COV-2 Antibodies.
Whole protein or long peptides in therapeutic vaccination strategies, does it make a difference?
Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19.
SARS-CoV-2 induces a durable and antigen specific humoral immunity after asymptomatic to mild COVID-19 infection
Immune responses after omicron infection in triple-vaccinated health-care workers with and without previous SARS-CoV-2 infection
SARS-CoV-2 induces a durable and antigen specific humoral immunity after asymptomatic to mild COVID-19 infection.
Immune responses after omicron infection in triple-vaccinated health-care workers with and without previous SARS-CoV-2 infection.
Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials.
Factors Associated With Serological Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Rituximab.
Impact of SARS-CoV-2 infection on vaccine-induced immune responses over time.
Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination.
Correlates of protection, viral load trajectories and symptoms in BA.1, BA.1.1 and BA.2 breakthrough infections in triple vaccinated healthcare workers
Duration of SARS-CoV-2 Immune Responses Up to Six Months Following Homologous or Heterologous Primary Immunization with ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccines.
Long-term SARS-CoV-2-specific and cross-reactive cellular immune responses correlate with humoral responses, disease severity, and symptomatology.
Elevated levels of MMP12 sourced from macrophages are associated with poor prognosis in urothelial bladder cancer
Symptoms and Functional Impairment Assessed 8 Months After Mild COVID-19 Among Health Care Workers
Symptoms and Functional Impairment Assessed 8 Months After Mild COVID-19 Among Health Care Workers.
Agonistic CD40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint blockade in glioma
Agonistic CD40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint blockade in glioma.
Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID‐19
Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2